

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4110999

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
RESVERLOGIX CORP.	03/01/2013
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	RVX THERAPEUTICS INC.
<b>Street Address:</b>	202,279 MIDPARK WAY SE
<b>City:</b>	CALGARY, AB
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	T2X 1M2
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14997213
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)408-4400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2024084000
<b>Email:</b>	bonny.rogers@finnegan.com
<b>Correspondent Name:</b>	FINNEGAN, HENDERSON
<b>Address Line 1:</b>	901 NEW YORK AVENUE NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20001
<b>ATTORNEY DOCKET NUMBER:</b>	12263.1006-01000
<b>NAME OF SUBMITTER:</b>	LESLIE A. MCDONELL
<b>SIGNATURE:</b>	/Leslie A. McDonell/
<b>DATE SIGNED:</b>	10/24/2016
<b>Total Attachments: 1</b>	
source=ASSIGNMENT2#page1.tif	

**ASSIGNMENT**

WHEREAS, Resverlogix Corp. (hereinafter referred to as Assignor), a corporation of Canada, whose post office address is 202,279 Midpark Way SE, Calgary, AB T2X 1M2 Canada, is the assignee of the entire right, title, and interest in U.S. Provisional Patent Application No. 61/745,274; and

WHEREAS, RVX Therapeutics Inc. (hereinafter referred to as Assignee), a corporation of Canada, whose post office address is 202,279 Midpark Way SE, Calgary, AB T2X 1M2 Canada, is desirous of securing the entire right, title, and interest in U.S. Provisional Patent Application No. 61/745,274;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, Assignor has sold, assigned, transferred, and set over, and does hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, its entire right, title, and interest in and to the letters patent and applications identified as U.S. Provisional Patent Application No. 61/745,274, in and including all countries of validation, and all divisions, continuations and continuations-in-part thereof, and all letters patent, which may be granted thereon, and all extensions, renewals, and reissues thereof, and all rights to claim priority on the basis of such patents and applications; and Assignee hereby authorizes and requests the respective patent offices throughout the world to issue all letters patent to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, ASSIGNOR HEREBY covenants that it has the full right to convey the interest assigned by this Assignment, and it has not executed and will not execute any agreement in conflict with this Assignment;

IN TESTIMONY WHEREOF, the undersigned authorized representatives of Resverlogix Corp. and RVX Therapeutics Inc. have hereunto set their respective hands,

Resverlogix Corp.

RVX Therapeutics Inc.

By: *[Signature]*  
Title: President / CEO  
Date: March 1, 2013

By: *[Signature]*  
Title: CEO  
Date: MARCH 1, 2013